Form 4: Oric Pharmaceuticals Director Acquires 35,000 Stock Options
SEC Form 4 Filing
Director Richard A. Heyman acquired 35,000 stock options in Oric Pharmaceuticals on January 2, 2025, according to a Form 4 filing.
Summary
- Richard A. Heyman, a director of Oric Pharmaceuticals, acquired 35,000 stock options on January 2, 2025.
- The options have an exercise price of $8.26.
- The options vest monthly over a year, starting January 2, 2025, and expire on January 1, 2035.
- Following the transaction, Heyman directly owns 35,000 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director is generally seen as a sign of confidence in the company's future, but it's a routine transaction.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates a director's increased stake in the company, which is generally viewed positively by investors.
Stakeholder Impact
- Shareholders may view the director's increased stake as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of earliest transaction: acquisition of stock options. |
| 01/02/2025 | Vesting start date for the stock options. |
| 01/06/2025 | Date of signature on the Form 4 filing. |
| 01/01/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.